Logo image of PRAX

PRAXIS PRECISION MEDICINES I (PRAX) Stock Fundamental Analysis

NASDAQ:PRAX - Nasdaq - US74006W2070 - Common Stock - Currency: USD

36.67  -1.64 (-4.28%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to PRAX. PRAX was compared to 561 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for PRAX as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, PRAX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year PRAX has reported negative net income.
In the past year PRAX has reported a negative cash flow from operations.
PRAX had negative earnings in each of the past 5 years.
PRAX had a negative operating cash flow in each of the past 5 years.
PRAX Yearly Net Income VS EBIT VS OCF VS FCFPRAX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

With a Return On Assets value of -44.40%, PRAX perfoms like the industry average, outperforming 51.52% of the companies in the same industry.
With a decent Return On Equity value of -48.40%, PRAX is doing good in the industry, outperforming 65.06% of the companies in the same industry.
Industry RankSector Rank
ROA -44.4%
ROE -48.4%
ROIC N/A
ROA(3y)-121.32%
ROA(5y)-88.85%
ROE(3y)-166.41%
ROE(5y)-118.06%
ROIC(3y)N/A
ROIC(5y)N/A
PRAX Yearly ROA, ROE, ROICPRAX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200 -250

1.3 Margins

PRAX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PRAX Yearly Profit, Operating, Gross MarginsPRAX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K -5K

More info and screens

8

2. Health

2.1 Basic Checks

PRAX does not have a ROIC to compare to the WACC, probably because it is not profitable.
PRAX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for PRAX has been reduced compared to 5 years ago.
PRAX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PRAX Yearly Shares OutstandingPRAX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
PRAX Yearly Total Debt VS Total AssetsPRAX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

An Altman-Z score of 8.22 indicates that PRAX is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 8.22, PRAX belongs to the best of the industry, outperforming 85.20% of the companies in the same industry.
There is no outstanding debt for PRAX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 8.22
ROIC/WACCN/A
WACC10.06%
PRAX Yearly LT Debt VS Equity VS FCFPRAX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

PRAX has a Current Ratio of 8.44. This indicates that PRAX is financially healthy and has no problem in meeting its short term obligations.
PRAX has a better Current ratio (8.44) than 74.51% of its industry peers.
PRAX has a Quick Ratio of 8.44. This indicates that PRAX is financially healthy and has no problem in meeting its short term obligations.
PRAX has a better Quick ratio (8.44) than 74.51% of its industry peers.
Industry RankSector Rank
Current Ratio 8.44
Quick Ratio 8.44
PRAX Yearly Current Assets VS Current LiabilitesPRAX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

4

3. Growth

3.1 Past

PRAX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 32.41%, which is quite impressive.
PRAX shows a strong growth in Revenue. In the last year, the Revenue has grown by 270.02%.
EPS 1Y (TTM)32.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-15.85%
Revenue 1Y (TTM)270.02%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, PRAX will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.23% on average per year.
Based on estimates for the next years, PRAX will show a very strong growth in Revenue. The Revenue will grow by 206.35% on average per year.
EPS Next Y-27.73%
EPS Next 2Y-10.92%
EPS Next 3Y-3.22%
EPS Next 5Y17.23%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y219.86%
Revenue Next 5Y206.35%

3.3 Evolution

PRAX Yearly Revenue VS EstimatesPRAX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
PRAX Yearly EPS VS EstimatesPRAX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 20 -20 -40 -60

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PRAX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PRAX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PRAX Price Earnings VS Forward Price EarningsPRAX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PRAX Per share dataPRAX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20

4.3 Compensation for Growth

PRAX's earnings are expected to decrease with -3.22% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.92%
EPS Next 3Y-3.22%

More info and screens

0

5. Dividend

5.1 Amount

PRAX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PRAXIS PRECISION MEDICINES I

NASDAQ:PRAX (5/23/2025, 9:30:29 AM)

36.67

-1.64 (-4.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-02 2025-05-02/bmo
Earnings (Next)08-11 2025-08-11/bmo
Inst Owners110.44%
Inst Owner Change8.52%
Ins Owners0.62%
Ins Owner Change1.94%
Market Cap739.27M
Analysts82.35
Price Target101.26 (176.14%)
Short Float %9.47%
Short Ratio3.36
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-1.01%
Min EPS beat(2)-1.25%
Max EPS beat(2)-0.77%
EPS beat(4)1
Avg EPS beat(4)-2.81%
Min EPS beat(4)-35.55%
Max EPS beat(4)26.31%
EPS beat(8)4
Avg EPS beat(8)4.99%
EPS beat(12)6
Avg EPS beat(12)3.07%
EPS beat(16)6
Avg EPS beat(16)-1.7%
Revenue beat(2)1
Avg Revenue beat(2)918.78%
Min Revenue beat(2)-100%
Max Revenue beat(2)1937.56%
Revenue beat(4)2
Avg Revenue beat(4)444.9%
Min Revenue beat(4)-100%
Max Revenue beat(4)1937.56%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-40.02%
EPS NQ rev (1m)-3.3%
EPS NQ rev (3m)-11.47%
EPS NY rev (1m)-4.31%
EPS NY rev (3m)-9.94%
Revenue NQ rev (1m)-58.33%
Revenue NQ rev (3m)-76.47%
Revenue NY rev (1m)-100%
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 91.02
P/FCF N/A
P/OCF N/A
P/B 1.68
P/tB 1.68
EV/EBITDA N/A
EPS(TTM)-10.72
EYN/A
EPS(NY)-12.63
Fwd EYN/A
FCF(TTM)-8.13
FCFYN/A
OCF(TTM)-8.13
OCFYN/A
SpS0.4
BVpS21.79
TBVpS21.79
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -44.4%
ROE -48.4%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-121.32%
ROA(5y)-88.85%
ROE(3y)-166.41%
ROE(5y)-118.06%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.44
Quick Ratio 8.44
Altman-Z 8.22
F-Score5
WACC10.06%
ROIC/WACCN/A
Cap/Depr(3y)38.78%
Cap/Depr(5y)139.93%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)32.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-15.85%
EPS Next Y-27.73%
EPS Next 2Y-10.92%
EPS Next 3Y-3.22%
EPS Next 5Y17.23%
Revenue 1Y (TTM)270.02%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y219.86%
Revenue Next 5Y206.35%
EBIT growth 1Y-79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-32.4%
EBIT Next 3Y-13.67%
EBIT Next 5Y-2.16%
FCF growth 1Y0.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-0.08%
OCF growth 3YN/A
OCF growth 5YN/A